NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Zymedi

Zymedi

Private
IncheonHealthcare & Life Scienceshttps://zymedi.com/

Last Round

Series A

Extension

May 30, 2023

Total Funding Raised

$28.85M

Company Overview

Zymedi is a biotechnology company that develops a novel therapeutics platform intended to improve the quality of life for people suffering from diseases by focusing on aminoacyl-tRNA synthetases (ARSs).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biopharmaceuticaldrug discoverymonoclonal antibodyaminoacyl-tRNA synthetasesARSpulmonary arterial hypertensionprecision medicinebiotechclinical-stagetherapeutic candidatedrug pipelineAI-enabled drug discoveryin-licensingpharma partneringbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Zymedi Comparables

Compare Zymedi with similar companies based on industry and business-model similarity.

Zymedi comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Zymedi Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionMay 30, 2023
Series AMar 26, 2021
AngelOct 1, 2020

Key People

Founding team and executive leadership

Sunghoon Kim

CEO

Executive Team

Nam Hoon Kwon

CTO EVP

Executive Team

Oliver Kim

Chief Financial Officer

Executive Team

Zymedi Investors

Notable investors and investment history

Zymedi investors
InvestorRounds
Company K Partners, LimitedSeries A, Series A Extension
CKD Venture CapitalSeries A Extension
UTC InvestmentSeries A, Series A Extension
Company K PartnersSeries A, Series A Extension
Medytox Venture InvestmentSeries A Extension
Korea Development BankSeries A Extension
Korea Venture Investment CorporationSeries A Extension

Zymedi Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Zymedi Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Zymedi's valuation, stock price, and market status.

Firmographic Details

HeadquartersIncheon
Employee Range10
Year Founded2019
Last FundingMay 30, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.